6.
Osugi Y, Hara J, Tagawa S, Takai K, HOSOI G, Matsuda Y
. Cytokine production regulating Th1 and Th2 cytokines in hemophagocytic lymphohistiocytosis. Blood. 1997; 89(11):4100-3.
View
7.
My L, Lien L, Hsieh W, Imamura T, Anh T, Anh P
. Comprehensive analyses and characterization of haemophagocytic lymphohistiocytosis in Vietnamese children. Br J Haematol. 2009; 148(2):301-10.
DOI: 10.1111/j.1365-2141.2009.07957.x.
View
8.
Vaiselbuh S, Bryceson Y, Allen C, Whitlock J, Abla O
. Updates on histiocytic disorders. Pediatr Blood Cancer. 2014; 61(7):1329-35.
DOI: 10.1002/pbc.25017.
View
9.
Janka G
. Familial and acquired hemophagocytic lymphohistiocytosis. Annu Rev Med. 2012; 63:233-46.
DOI: 10.1146/annurev-med-041610-134208.
View
10.
Henter J, Horne A, Arico M, Egeler R, Filipovich A, Imashuku S
. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2006; 48(2):124-31.
DOI: 10.1002/pbc.21039.
View
11.
Davi S, Consolaro A, Guseinova D, Pistorio A, Ruperto N, Martini A
. An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol. 2011; 38(4):764-8.
DOI: 10.3899/jrheum.100996.
View
12.
Minoia F, Bovis F, Davi S, Insalaco A, Lehmberg K, Shenoi S
. Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome. J Pediatr. 2017; 189:72-78.e3.
DOI: 10.1016/j.jpeds.2017.06.005.
View
13.
Weiss E, Girard-Guyonvarch C, Holzinger D, de Jesus A, Tariq Z, Picarsic J
. Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome. Blood. 2018; 131(13):1442-1455.
PMC: 5877443.
DOI: 10.1182/blood-2017-12-820852.
View
14.
Teachey D, Rheingold S, Maude S, Zugmaier G, Barrett D, Seif A
. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013; 121(26):5154-7.
PMC: 4123427.
DOI: 10.1182/blood-2013-02-485623.
View
15.
Suntharalingam G, Perry M, Ward S, Brett S, Castello-Cortes A, Brunner M
. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006; 355(10):1018-28.
DOI: 10.1056/NEJMoa063842.
View
16.
Stepp S, Le Deist F, Bhawan S, Certain S, Mathew P, Henter J
. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science. 1999; 286(5446):1957-9.
DOI: 10.1126/science.286.5446.1957.
View
17.
Bossi G, Griffiths G
. Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T cells and natural killer cells. Nat Med. 1999; 5(1):90-6.
DOI: 10.1038/4779.
View
18.
Fisher G, Rosenberg F, Straus S, DALE J, Middleton L, Lin A
. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell. 1995; 81(6):935-46.
DOI: 10.1016/0092-8674(95)90013-6.
View
19.
Oliveira J, Bleesing J, Dianzani U, Fleisher T, Jaffe E, Lenardo M
. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood. 2010; 116(14):e35-40.
PMC: 2953894.
DOI: 10.1182/blood-2010-04-280347.
View
20.
Feldmann J, Callebaut I, Raposo G, Certain S, Bacq D, Dumont C
. Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell. 2003; 115(4):461-73.
DOI: 10.1016/s0092-8674(03)00855-9.
View